Zomedica Corp
AMEX:ZOM
Net Margin
Zomedica Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
Z
|
Zomedica Corp
AMEX:ZOM
|
53.9m USD |
-233%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
238B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
186.8B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
153.4B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
147.2B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.6B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.5B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.8B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.6B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
272.6B CNY |
31%
|
Zomedica Corp
Glance View
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 85 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Zomedica Corp's most recent financial statements, the company has Net Margin of -232.7%.
You don't have any saved screeners yet